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1. Introduction 
Cancer is a leading cause of death in the world. The incidence of cancers is related to 
environmental factors, behavioral patterns, and genetic disorders. Cancer therapy usually 
aims to selectively destroy cancer cells while sparing normal tissue. Most chemotherapeutic 
agents function by damaging cancer cell DNA. The cellular responses to DNA damage are 
thus critical factors for determining the effectiveness of most cancer therapies (Ashworth, 
2008). When normal cells are exposed to damage, DNA repair mechanism is induced. The 
DNA repair processes are the cellular responses associated with the restoration of the 
normal DNA nucleotide sequences. The DNA repair activity of the cell is an important 
determinant of a cells sensitivity to chemotherapeutic agents. It is known that resistance to 
DNA-damaging agents can be associated with increased cellular repair activities, while 
defects in DNA repair pathways result in hypersensitivity to damage (Kelley & Fishel, 2008; 
Quinn et al., 2003, 2009). Several studies have clearly demonstrated that the impairment or 
absence of genes or proteins responsible for DNA damage repair, frequently causes genomic 
instability, cell cycle arrest and apoptosis. The importance of these repair pathways is 
highlighted by the fact that more than 100 genes have been found in mammalian cells that 
are involved in some way in DNA damage repair pathways. The breast cancer susceptibility 
gene 1 (BRCA1) is a tumor suppressor gene involved in maintaining genomic integrity 
through multiple functions in DNA damage repair, transcriptional regulation, a cell cycle 
checkpoint and protein ubiquitination (Brzovic et al., 2001; Hashizume et al., 2001; Mark et 
al., 2005; Varma et al., 2005; Williams et al., 2004). In cancer cells, damage to BRCA1 by the 
anticancer platinum drug cisplatin may lead to a loss of such functions and ultimately 
results in cancer cell death. In addition, preclinical and clinical studies have recently 
revealed that inactivation of the BRCA1 protein in cancer cells leads to chemosensitivity. 
Therefore, approaching the BRCA1 protein as a potential therapeutic target for cisplatin or 
other such platinum based drugs might be of interest for molecular-targeted cancer therapy. 
In this chapter, the biophysical characterization and functional consequences of the human 
BRCA1 gene and the BRCA1 RING protein induced by cisplatin are described.  
2. Breast cancer susceptibility gene 1 (BRCA1) and its encoded protein 
In 1990, chromosome 17q21 was identified by linkage analysis as the location of a breast cancer 
susceptibility gene 1 or BRCA1 (Hall et al., 1990). The entire gene covers approximately 100 kb 
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of genomic sequence, and was subsequently cloned four years later (Miki et al., 1994). BRCA1 
is a tumor suppressor gene composed of 24 exons, with an mRNA that is 7.8 kb in length, and 
22 coding exons that translate into a protein of 1863 amino acids (Fig. 1) with a molecular 
weight of 220 kDa (Brzovic et al., 1998). It has 3 major domains, including (1) the N-terminal 
RING finger domain (BRCA1 RING domain), (2) the large central segment with the nuclear 
localization signal (NLS), and (3) the BRCA1 C-terminal domain (BRCT). The BRCA1 protein 
plays an essential role in maintaining genomic stability associated with a number of cellular 
processes, including DNA repair, a cell cycle checkpoint, transcriptional regulation, and 
protein ubiquitination (Huen et al., 2010; O'Donovan & Livingston, 2010). 
 
 
Fig. 1. Scheme of BRCA1 mRNA and sites of protein interaction 
2.1 The BRCA1 RING domain 
The N-terminal RING finger domain contains the conservative sequences of cysteine and 
histidine residues (C3HC4) necessary for specific coordination with two Zn2+ ions. The first 
109 amino acids of BRCA1 protein constitute a protease-resistance domain. The solution 
structure of the BRCA1 RING domain revealed the existence of antiparallel ǂ-helices at both 
ends, flanking the central RING motif (residues 24-64) and was characterized by a short 
antiparallel three-stranded ǃ-sheet, and two large Zn2+-binding loops, and a central ǂ-helix 
(Brzovic et al., 2001)The two Zn2+-binding sites are formed in an interleaved fashion in 
which the first and third pairs of cysteines (Cys24, Cys27, Cys44, and Cys47) form site I, and 
the second and fourth pairs of cysteines and a histidine (Cys39, His41, Cys61, and Cys64) 
form site II. It is an important domain since it might mediate a central role in 
macromolecular interactions to exert the tumor suppression functions. The solution 
structure together with yeast-two-hybrid studies revealed that the BRCA1 RING domain 
preferentially formed a heterodimeric complex with another RING domain BARD1 (BRCA1-
associated RING domain 1) through an extensive four-helix-bundle interface (Brzovic et al., 
2001; Wu et al., 1996). The binding interface is composed of residues 8-22 and 81-96 of 
BRCA1, and residues 36-48 and 101-116 of BARD1. The BRCA1-BARD1 complex requires 
each other for their mutual stabilities, and they are co-localized in nuclear dots during S 
phase but not the G phase of the cell cycle and in nuclear foci (Hashizume et al., 2001). The 
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progression to S phase by aggregation of nuclear BRCA1 and BARD1 implied the 
importance of both proteins for a DNA repair function (Jin et al., 1997). The BRCA1-BARD1 
complex also exhibits enzymatic activity of an E3 ubiquitin ligase that specifically transfers 
ubiquitin to protein substrates that are essential for cellular viability (Hashizume et al., 2001; 
Xia et al., 2003). Cancer-predisposing mutations in the Zn2+-binding sites were demonstrated 
not only to alter the affinity for Zn2+ and the native BRCA1 RING structure but also 
abolished the interaction with BARD1 and the E3 ligase activity (Morris et al., 2006). The 
results supported the importance of Zn2+ as a structural component, as it obviously played a 
critical role in the stabilization of the structure and function of the BRCA1 RING domain. 
2.2 The large central segment of BRCA1 
The central segment of BRCA1 covers exon 11 (approximately 3500 bp) and constitutes 
approximately 60 percent of the coding region of the gene. Deletion of exon 11 results in 
removal of the nuclear localization signal of BRCA1. Biophysical characterization revealed 
that this domain was intrinsically disordered or natively unfolded under physiological 
conditions. This might potentially allow the BRCA1 central region to act as a long flexible 
scaffold, to mediate interactions with DNA, and perhaps a number of other proteins 
involved in the DNA damage response and repair (Mark et al., 2005). The reported binding 
partners to the central region were c-Myc, RB, p53, FANCA, RAD50, RAD51, JunB, and 
BRCA2 (Rosen et al., 2003). Recently, the BRCA1 central region has been shown to efficiently 
interact with p53, and stimulate p53-mediated DNA binding and transcriptional activities 
(Buck, 2008). This result indicated that the BRCA1 central segment facilitated the induction 
of cell cycle arrest and apoptosis in response to DNA damage. Furthermore, the 
association between the central region of BRCA1 and PALB2 (partner and localizer of 
BRCA2, also known as FANCN) was observed primarily through apolar bonding between 
their respective coiled-coil domains (Sy et al., 2009). PALB2 binds directly to BRCA1, and 
serves as the molecular scaffold for the formation of the BRCA1-PALB2-BRCA2 complex. 
BRCA1 mutations (L1407P and M1411T) identified in cancer patients were shown to 
disrupt the specific interaction between BRCA1 and PALB2, resulting in a defective 
homologous recombination (HR) repair and a compromised cell survival after DNA 
damage (Sy et al., 2009).  
2.3 The BRCA1 C-terminal domain 
The C-terminal region (residues 1646-1863) of BRCA1 contains two BRCT (BRCA1 C-
terminal) domains in tandem (motif 1: amino acids 1653-1736; motif 2: amino acids 1760-
1855). Each BRCT domain is characterized by a central, parallel four-stranded ǃ-sheet with a 
pair of ǂ-helices (ǂ1 and ǂ3) packed against one face, and a single ǂ-helix (ǂ2) packed 
against the opposite face of the sheet (Williams et al., 2001). The two BRCA1-BRCT repeats 
interact in a head-to-tail fashion. This domain serves as a multipurpose protein-protein 
interaction module that binds to other BRCT repeats or other protein domains with 
apparently unrelated structures (Watts & Brissett, 2010). Based on its physical interactions 
with other proteins, BRCA1 has been implicated in a wide array of cellular functions, 
including cell cycle regulation, DNA damage response, transcriptional regulation, 
replication and recombination, and higher chromatin hierarchical control (Starita & Parvin, 
2003). The BRCA1-BRCT domain has been identified as a phosphopeptide recognition 
module, and is demonstrated to bind to the phosphorylated protein partners (BACH1 and 
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CtIP, containing the consensus sequence pSer-X-X-Phe) that is involved mainly in the 
control of the G2/M phase checkpoint and DNA damage repair (Varma et al., 2005; 
Williams et al., 2004). Several cancer-predisposing mutations in the BRCA1-BRCT domain 
resulted in destabilization of the structural integrity at the BRCT active sites, and abolished 
their affinities to synthetic BACH1 and CtIP phosphopeptides (Rowling et al., 2010). These 
findings provide a better understanding of the pathogenic BRCA1 mutations on functional 
mechanisms and tumorigenesis. 
3. BRCA1 and DNA damage repair 
A substantial amount of evidence that has implicated BRCA1 in the DNA damage repair 
pathways has been documented. BRCA1 co-localizes with RAD51 and BARD1 to nuclear 
foci (sites associated with repair of DNA caused by the damaging agents or Ǆ-irradiation) 
(Hashizume et al., 2001; Scully et al., 1997). The nuclear foci is marked by the histone variant 
H2AX that was phosphorylated on Ser139 (known as ǄH2AX) (Rogakou et al., 1998). ǄH2AX 
is one of the initial recruiting factors for various checkpoints and DNA repair proteins, 
including Abraxas, RAP80, and BRCA1, at sites of DNA breaks (Foulkes, 2010). The H2AX 
signaling cascade begins to emerge with the finding that MDC1 (mediator of DNA damage 
checkpoint 1) is the main downstream factor in the pathway, and is required for the 
damage-induced focal accumulation of a number of DNA damage repair factors at the DNA 
breaks (Stucki et al., 2005).  
BRCA1 plays a role in maintaining genome integrity through its role in DNA damage 
repair. Several observations have implicated BRCA1 in homologous recombination (HR), 
non-homologous end-joining (NHEJ and nucleotide excision repair (NER). A role for 
BRCA1 in HR-mediated repair is involved through its stable complex formation with 
BRCA2, which has a well-defined role in HR through its direct interaction with RAD51 
(Bhattacharyya et al., 2000). RAD51 (the mammalian homolog of the Escherichia coli RecA 
protein) is a DNA recombinase that catalyzes strand exchange in an early step of HR 
(Baumann et al., 1996). PALB2 (the partner and localizer of BRCA2) has recently been 
identified as the bridging factor required for the BRCA1-BRCA2 association (Rahman et al., 
2007). The BRCA1-PALB2 interaction was mediated by their respective coiled-coil domains, 
and was found to promote HR-mediated repair (Rahman et al., 2007). Importantly, missense 
mutations identified in the PALB2-binding region on BRCA1 disrupted the specific 
interaction of BRCA1 with PALB2, and compromised DNA repair in a gene conversion 
assay (Sy et al., 2009). Although these studies have revealed a molecular link between 
BRCA1 function and HR-mediated repair, the mechanism by which BRCA1 promotes HR 
through the PALB2-BRCA2-RAD51 axis remains unclear. 
As an alternative to HR, there is a growing body of evidences, to indicate that a component of 
NHEJ is regulated by BRCA1. The exact role of BRCA1 in NHEJ, however, has not been well 
defined (Zhang & Powell, 2005). In the NHEJ pathway, the DNA-dependent protein kinase 
catalytic subunit (DNA-PKcs) and a Ku heterodimer of Ku80 and Ku70 are recruited to the 
sites of DNA DSBs for preparing the DNA ends before ligation by the XRCC4 ligase IV. The 
most possible explanation for BRCA1 being involved in NHEJ is its association with a NHEJ 
factor Ku80 (Chiba & Parvin, 2001; Wei et al., 2008). Many studies have provided strong 
evidences that the NHEJ pathway was impaired, both in vivo and in vitro, in BRCA1-deficient 
mouse embryonic fibroblasts and in the human breast cancer cell line HCC1937 which carries 
a homozygous mutation in the BRCA1 gene (Bau et al., 2004; Zhong et al., 2002).  
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4. BRCA1 and transcriptional regulation 
As described earlier, BRCA1 contains a C-terminal transactivation domain as was first 
defined using the yeast two-hybrid system (Chapman & Verma, 1996; Monteiro et al., 1996). 
The transactivation domain was mapped to the region of the protein encoded by exons 21-
24 using deletion constructs of BRCA1 fused to the GAL4 DNA binding domain. The 
BRCA1-BRCT domain has been implicated in the regulation of transcription of several genes 
responsible for DNA damage. The ability of BRCA1 to act as either a co-activator or a co-
repressor of transcription may involve its ability to recruit the basal transcriptional 
machinery and other proteins that have been implicated in chromatin remodeling (Mullan et 
al., 2006). BRCA1 was capable of activating the p21 promoter (Somasundaram et al., 1997). 
One report claimed that BRCA1 participated in the stabilization of p53 in response to DNA 
damage, and served as a co-activator for p53 (Zhang et al., 1998). The interaction of BRCA1 
and p53 potentially resulted in the redirection of p53-mediated transactivation from a pro-
apoptotic target to genes involved in DNA repair and cell cycle arrest (Zhang et al., 1998). In 
addition, BRCA1 has been shown to interact with the RNA polymerase II holoenzyme 
(Scully et al., 1997). However, BRCA1 could repress the transcription of an estrogen receptor 
α (ERα) and its downstream estrogen responsive genes (Fan et al., 1999). The transcriptional 
repression activity of BRCA1 for ERα occurs by the association of the N-terminus of BRCA1 
(residues 1-300) with the C-terminal activation function (AF-2) of ERα. Breast cancer-
associated mutations of BRCA1 were found to abolish its ability to inhibit ERα activity (Fan 
et al., 2001). The repression activity exerted by BRCA1 involved the ability of BRCA1 to 
down-regulate levels of the transcriptional coactivator p300, which has also been shown to 
interact with the AF-2 domain of ERα (Fan et al., 2002). Further investigations revealed that 
overexpression of BRCA1 could inhibit the recruitment of the co-activators [steroid receptor 
co-activator 1 (SRC1), and amplified breast cancer 1 (AIB1)], and enhanced the recruitment 
of a co-repressor [histone deacetylase 1 (HDAC1)] to the progesterone response elements 
(PRE) of c-Myc.  
5. BRCA1 and protein ubiquitination 
The BRCA1 protein displays an E3 ubiquitin ligase activity through its RING domain, and 
this activity is enhanced when it exists as a heterodimer with the BARD1 RING domain (Xia 
et al., 2003). In vitro and in vivo studies have indicated that the BRCA1-BARD1 complex 
was capable of autoubiquitination that paradoxically stabilized the protein complex, and 
that also activated its in vitro E3 ligase activity with other proteins  (Chen et al., 2002; Wu-
Baer et al., 2010). However, the substrate specificity of the BRCA1 E3 ligase activity and its 
biological relevance to tumor suppression function are still unknown. Putative substrates for 
ubiquitination by the BRCA1-BARD1 RING complexes have recently emerged from in vitro 
and in vivo studies such as the nucleosomal histones H2A and its variant H2AX, RNA 
polymerase II, γ-tubulin, nucleophosmin/B23, and estrogen receptor α (ERα) (Eakin et al., 
2007; Horwitz et al., 2007; Parvin, 2009; Sato et al., 2004; Starita et al., 2005; Thakar et al., 
2010). BRCA1 can form a RING heterodimer E3 ligase activity with BARD1, and this is 
required for the recruitment of BRCA2 and RAD51 to damaged sites for HR repair 
(Ransburgh et al., 2010). Many cancer-predisposing mutations in the BRCA1 RING domain, 
that inhibited the E3 ligase activity and its ability to accumulate at damaged sites, were 
defective in homologous recombination that is critical for tumor suppression (Morris et al., 
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2006, 2009; Ransburgh et al., 2010). Moreover, BRCA1 accumulation at the sites of DSBs 
occurred rapidly (within 20 s), and the RING structure was required (residue 1-200 of 
BRCA1) for the rapid recruitment with Ku80 at damaged sites in response to non-
homologous end joining (Wei et al., 2008). Missense mutations in the BRCA1 RING domain 
significantly reduced their accumulations at DSBs, and abolished the association with Ku80. 
Therefore, the loss of the BRCA1 E3 ligase activity rendered cancerous cells hypersensitive 
to DNA-damaging agents,and clearly demonstrated a significant role for ubiquitnation in 
the DNA damage response and DNA repair activity (Ransburgh et al., 2010; Ruffner et al., 
2001). Thus ubiquitination is involved in key steps that properly conduct the DNA repair 
process after DSBs.  
Several reports have shown that the BRCA1 E3 ligase was capable of in vitro 
monoubiquitination of histones H2A and its variant H2AX (Thakar et al., 2010). This 
implied a BRCA1 function in regulating chromatin structure in the context of transcriptional 
regulation and DNA repair. Hyperphosphorylated RNA polymerase II (RNAPII) at its 
carboxyl terminal domain (CTD), consists of multiple repeats of the heptapeptide 
(YSPTSPS), involved in a generalized response to UV irradiation. It also served as a 
substrate for the BRCA1-dependent ubiquitination that was proposed to facilitate BRCA1 
function in DNA repair by inhibiting DNA transcription, and then recruiting other DNA 
repair proteins at a lesion (Starita et al., 2005). Recently, It was found that the BRCA1-
mediated ubiquitination of RNAPII prevented a stable association of some transcription 
factors (TFIIE and TFIIH) in the transcriptional preinitiation complex, and thus blocked the 
initiation of mRNA synthesis (Horwitz et al., 2007). Ubiquitination of the preinitiation 
complex was not targeting proteins for degradation by proteasome but rather the ubiquitin 
moiety itself interfered with the assembly of basal transcription factors at the promoter 
(Horwitz et al., 2007). Nucleoplasmin B23 and γ-tubulin were found to be the candidate 
substrates of the BRCA1 E3 ligase activity in vivo (Parvin, 2009; Sato et al., 2004). Both proteins 
were present in centrosomes, and apparently were not targeted for degradation by BRCA1-
mediated modifications. The results indicated that ubiquitination of nucleoplasmin B23 and γ-
tubulin played a vital role in regulating the centrosome number and maintenance of genomic 
stability by unknown mechanisms. Recently, the BRCA1 protein has been shown to inhibit 
ERα transcriptional activity, and to induce repression of estrogen response genes and cell 
proliferation (Xu et al., 2005). A potential explanation for the regulation of estrogen signaling 
by BRCA1 was the ERα ubiquitination and degradation mediated by the BRCA1 E3 ligase 
activity (Dizin & Irminger-Finger, 2010; Eakin et al., 2007). Conversely, the BRCA1-associated 
protein 1 (BAP1) is a deubiquitinating enzyme that can interact with the BRCA1 RING domain 
(Jensen et al., 1998). It was shown that BAP1 inhibited the BRCA1 autoubiquitination, and the 
nucleophosmin/B23 ubiquitination mediated by the BRCA1 E3 ligase activity (Nishikawa et 
al., 2009). Down-regulation of BAP1 in cells also resulted in the retardation of the S phase and 
ionizing irradiation hypersensitivity, a phenotype similar to BRCA1 deficiency. This again 
indicated that the BRCA1-BARD1 complex and the BAP1 protein coordinately regulated 
ubiquitination during a DNA damage response and the cell cycle.  
6. Cisplatin 
Cisplatin [cis-diamminedichloroplatinum(II)] is the platinum-based anticancer drug and is 
most effective in the treatment of metastatic testiscular cancers, ovarian, head, neck, bladder, 
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cervical and lung cancers (Kelland, 2007). Although widely used as a well established 
anticancer drug in cancer chemotherapy, cisplatin displays major toxic side effects, such as 
nephrotoxicity, nausea and vomiting and neurotoxicity. In addition to its toxic side effects, a 
major limitation of cisplatin chemotherapy is the development of genetic mechanisms of 
resistance. The effectiveness of cisplatin depends on the drug uptake, and the actual amount 
that reacts with cellular targets.  
6.1 Cisplatin-DNA adducts 
It is generally accepted that DNA is the most important intracellular target of cisplatin. 
When cisplatin is dissolved in aqueous solution, chloride ions are displaced to allow the 
formation of aquated species, which are the reactive forms of the compound (Pinto and 
Lippard, 1985). The concentration of chloride ions influences the reactivity of cisplatin. After 
intravenous administration it is relatively less reactive in the extracellular space where the 
physiological chloride concentration is about 100 mM, but on crossing the plasma 
membrane, it is activated in the intracellular space where the chloride concentration drops 
to 2-3 mM. Chlorine groups of cisplatin are easily replaced by water molecules to allow the 
formation of aqauted species in a stepwise manner. Activated cisplatin is a potent 
electrophile that will react with any nucleophile, including the sulfhydryl groups on 
proteins and nucleophilic groups on nucleic acids. DNA is attacked by activated cisplatin at 
guanine residues in position N7, in double stranded DNA from the side of the major groove. 
The attack is apparently preceeded by an electrostatic attraction between the positively 
charged platinum (II) complex and the negatively charged phosphodeoxyribose DNA 
backbone and facilitated by bidirectional diffusion along the backbone. The initial attack of 
DNA by activated cisplatin is followed by the replacement of the remaining chloro ligand 
before the adduct forms an intramolecular attack on a second purine residue (either guanine 
or adenine). The hydration rate constant of the monoaqua form was faster than that of 
diaqua form (2.38x10-5 s-1 compared to 1.4x10-5 s-1) (Cubo et al., 2009).  
The anticancer activity of cisplatin potentially results from the modification of DNA through 
a covalent cross-link or platinum (Pt)-DNA adduct (Fig. 2). The DNA adducts interfere with 
DNA replication and transcription, and ultimately lead to cell death by cancer (Ahmad, 
2010; Wang & Lippard, 2005). The predominant adducts formed by cisplatin in vitro are 1,2-
intrastrand crosslinks. Quantitative studies show that the 1,2-intrastrand d(GpG), and 
d(ApG) crosslinks account for 65% and 25%, respectively (Fichtinger-Schepman et al., 1985; 
Eastman, 1986). They alter the DNA structure, block replication and transcription and activate 
a programmed cell death (apoptosis). X-ray diffraction of the crosslinked dinucleotide cis-
Pt(NH3)2[d(pGpG)] reveals that the intrastrand cisplatin crosslink produces a severe local 
distortion in the DNA double helix, leading to unwinding and kinking. These crosslinks bend 
and unwind the duplex. The altered structure is recognized by high-mobility-group (HMG) 
proteins and other proteins. The binding of HMG proteins to cisplatin-modified DNA has 
been postulated to potentiate the anticancer activity of the drug. 
6.2 Cisplatin-protein adducts 
The interaction of cisplatin with proteins is of particular significance, and is believed to play 
an important role in distribution of the drug and the inactivation responsible for 
determining its efficacy and toxicity (Casini et al., 2008; Sun et al., 2009; Timerbaev et al., 
2006). It is intriguing, that protein adducts affect some crucial aspects of protein structure  
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Fig. 2. Common cisplatin-DNA adducts 
and functions. For instance, the platination of human serum albumin caused partial 
unfolding of the protein structure at a high drug concentration, and induced intermolecular 
crosslinks possibly at Cys34 and/or Met298 via bifunctional adducts or via NH3 release 
(Ivanov et al., 1998; Neault & Tajmir-Riahi, 1998). Myoglobin, a small protein, containing a 
heme group required for the transport of oxygen in skeletal muscles and myocardial cells, 
formed intramolecular mono- and bi-functional adducts with cisplatin. Its putative 
platinum-binding sites were His116 and His119 (Zhao & King, 2010). A number of 
intramolecular crosslinks also occurred with ubiquitin adducts (Casini et al., 2009). The loss 
of activity of the C-terminal heat shock protein 90 after protein aggregation was reported to 
be a consequence of cisplatin binding but it did not exhibit any conformational change 
(Ishidaa et al., 2008). It is intriguing, that cisplatin can cause a structural perturbation of a 
synthetic peptide containing a Zn2+ finger domain. The platinum coordinates to Zn2+-
binding sites to induce Zn2+ ejection and subsequently the loss of the protein tertiary 
structure. This implies that cisplatin can inhibit critical biological functions regulated by 
Zn2+ finger proteins. Such a mechanism has been discussed in the apoptosis process 
mediated by the interaction of cisplatin and platinum-based compounds with Zn2+ finger 
transcriptional factors (Bose et al., 2005). Likewise, the nucleocapsid Zn2+ finger NCp7 
protein, a protein required for the recognition and packaging of viral RNA, became attached 
to some platinum compounds, when its ability to bind nucleic acid was changed and 
prevented viral infectivity (de Paula et al., 2009; Musah, 2004).  
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7. BRCA1 and its encoded product as potentially molecular targets for 
cisplatin for cancer therapy 
In recent years, there has been significant progress made in evaluating what happens when 
BRCA1 is inactivated so it cannot respond  to DNA damage in cancer cells, in other words, 
taking advantage of the inherent weakness of the BRCA1 dysfunction in cancer cells. These 
cells have increased sensitivity to DNA-damaging agents that eventually result in major 
genomic instability and cell death (Amir et al., 2010; Ashworth, 2008; Helleday et al., 2008; 
Lieberman, 2008; Powell & Bindra, 2009; Quinn et al., 2009; Tassone et al., 2009; Zhu et al., 
2009). Cancerous cells with inactivated BRCA1 had defects in DNA repair of double strand 
breaks (DSBs) (Farmer et al., 2005; Kennedy et al., 2004; Litman et al., 2008). Moreover, 
extensive investigations have revealed the relevance of the BRCA1-mediated ubiquitination 
to DNA repair functions. Mutations in the BRCA1 RING domain resulted in the loss of the 
E3 ubiquitin ligase activity, and conferred hypersensitivity of the cancerous cells to DNA-
damaged chemotherapy and γ-irradiation (Ransburgh et al., 2010; Ruffer et al., 2001; Wei et 
al., 2008). 
It was initially reported that overexpression of BRCA1 in the human breast cancer MCF7 
cell line resulted in an increased resistance to cisplatin (Husain et al., 1998). Furthermore, 
antisense or siRNA-based inhibition of endogenous BRCA1 expression promoted the 
increased sensitivity to cisplatin that was associated with the decreased DNA repair by 
NER and an increased apoptosis (Lafarge et al., 2001; Quinn et al., 2003). This indicates 
that the reduced BRCA1 expression observed in sporadic cancers may also be exploited 
for DNA damage-based chemotherapy (James et al., 2007; Quinn et al., 2009). In a similar 
situation, BRCA1-deficient mouse embryonic stem cells displayed defective DNA repair 
and a 100-fold increased sensitivity to the alkylating agent mitomycin C and cisplatin than 
those containing wild-type BRCA1 (Bhattacharyya et al., 2000; Moynahan et al., 2001). 
This sensitivity was reversed upon correction of the BRCA1 mutation in mouse embryonic 
fibroblast cells with a disrupted BRCA1 (Fedier et al., 2003). Reconstitution of BRCA1 in 
the cells via transfection meant that BRCA1 functions were regained, and resulted in a 
reduced level of cancer cell death, following treatment with cisplatin or other DNA 
damaging agents (Quinn et al., 2003). Moreover, more recent evidence has revealed the 
implication of BRCA1 in cisplatin-resistant breast and ovarian cancer cell lines. These cells 
that acquired resistance to DNA-damaging agents was mediated by a secondary mutation 
in BRCA1. This mutation restored the BRCA1 protein expression and function for DNA 
repair, causing the cancer cells to become more tolerant to cisplatin (Swisher  et al., 2008; 
Tassone et al., 2003; Wang & Figg, 2008). Recently, a number of clinical studies have 
examined the utilization of this BRCA1 dysfunction in response to the DNA-damaging 
drug cisplatin. A pathological complete response (pCR) with excellent compliance was 
observed in cancer patients with BRCA1 mutations (Byrski et al., 2009; Font et al., 2010; 
Quinn et al., 2007; Silver et al., 2010; Taron et al., 2004). This indicates that patients with 
BRCA1 dysfunction gain more benefit from treatments that exert their effects by causing 
DNA damage.  
Therefore, it is important to continue elucidating BRCA1/BRCA1-dependent pathways to 
design molecular–targeted therapy for the platinum treatment of cancer cells by taking 
advantage of their impairment of the BRCA1/BRCA1 repair capacity and BRCA1-
dependent ubiquitination inactivated by cisplatin.  
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7.1 Cellular repair of cisplatin-damaged BRCA1  
Preliminary results from our laboratory have  indicated that the cisplatin-modified BRCA1 
gene sequence was resistant to restriction endonuclease cleavage, and indicated that 
cisplatin preferentially formed 1,2-intrastrand d(GpG) cross-links (Ratanaphan et al., 2009). 
The drug inhibited BRCA1 amplification in a dose-dependent manner. It has been found 
that cisplatin-treated, BRCA1 exon 11, of adenocarcinoma MCF-7 cells exhibited a time 
dependent recovery after drug exposure to the cells at 37°C for 6 h, with an initial low level 
of lesion removal during the first 4 h (Fig. 3). A more complete lesion removal was observed 
with over 90% of 50 µM cisplatin after 18 h of repair time. However, only 30% of the lesion 
repair was observed at a higher cisplatin concentration of 200 µM (Ratanaphan et al., 2009). 
From a host cell reactivation assay, the result indicated that a reduction in cellular 
reactivation of the drug-damaged reporter gene encoding plasmid was a consequence of an 
increase in platination levels within the transcribed reporter gene. This indicated that the 
cellular response to cisplatin reflected its intrinsically low capacity for removal of cisplatin-
BRCA1 adducts. Following cisplatin-induced BRCA1 adducts, a number of cellular repair 
proteins, excluding BRCA1, are responsible for recognizing and processing the removal of 
DNA damage. NER is a major process for removing platinum-damaged DNA. This process 
requires an ATP-dependent multiple protein complex that recognizes the bending induced 
on DNA by cisplatin. The NER complex has a dual role that can unwind the DNA strands 
(helicase), and excise the damage strand (endonuclease) of about 24-32 nucleotides in length, 
containing a platinum lesion. DNA resynthesis factors are recruited at the site of the incised 
DNA, and employ the opposite strand as template to fill in the gap in concert with DNA 
ligases. Two distinct sub-pathways of NER that may be involved, are transcription-coupled 
repair (TCR) and/or global genomic repair (GGR). TCR preferentially repairs transcribed 
strands of the RNA polymerase II-transcribed active gene, while GGR repairs throughout 
the genome (Shuck et al., 2008). Recently, the suppression of ERCC1 expression in a HeLa S3 
cell line by small interfering RNA (siRNA) led to a decrease in the repair activity of 
cisplatin-induced DNA damage along with a decrease in cell viability against platinum-  
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Fig. 3. Cellular repair of cisplatin-damaged 3,426-bp BRCA1 exon 11. MCF-7 cells were 
incubated with medium plus cisplatin at various concentrations (50–200 μM) for 6 h. The 
cells were washed twice with PBS and fresh medium was added. The genomic DNA was 
then extracted at 2, 4, 8 and 18 h and used as the template for the QPCR assay (Ratanaphan 
et al., 2005, 2009).   
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based drugs (Chang et al., 2005). Recombination pathways can also be involved as repair 
systems responsible for DNA damage induced by the anticancer drug cisplatin. 
Recombination-deficient E. coli mutants were sensitive to cisplatin and exhibited a decreased 
survival by four orders of magnitude in comparison with the parental strain at a cisplatin 
concentration of 75-80 µM (Zdraveski et al., 2000). Many recombination-deficient strains 
showed a sensitivity to the drug equal to that of the NER-deficient strains. Double 
mutations in recombination and NER proteins were approximately 4-fold more sensitive to 
cisplatin than the corresponding single mutants. This indicates that recombination and NER 
pathways play roles that are independent of each other in protecting cells from cisplatin-
induced damage. Impaired recombination DNA repair in yeast and prostate cancer cell lines 
also showed an increased sensitivity to cisplatin (Wang et al., 2005).  
7.2 Inhibition of BRCA1 transcriptional transactivation  
The one hybrid GAL4 transcription assay is used to study the effect of cisplatin on 
transcriptional transactivation. The level of transcriptional transactivation is inversely 
proportional to the amount of platinum-BRCA1 adducts. The results are most likely due to 
inhibition of transcription of the reporter plasmid that resulted from interstrand crosslinks 
(Ratanaphan et al., 2009). The transcriptional transactivation activity of BRCA1 has 
previously been reported by fusing the C-terminal domain of BRCA1 to a heterogenous 
DNA-binding domain (Chapman and Verma, 1996). The BRCT domain (amino acids 1380-
1863) of human BRCA1 scores positively in transcriptional activation trap experiments using 
various forms of so-called “one hybrid assay”.The BRCA1-fused DNA-binding domain 
activates transcription in a cell-free system to a similar extent as a dose of the powerful 
activator, VP16 (Scully et al., 1997). A GAL4:BRCA1 has also been introduced in yeast- and 
mammalian-based transcription assays to characterize the deleterious mutations in the 3/ -
terminal region of the BRCA1 (Vallon-Christersson et al., 2001). The transcriptional activity 
reflects a tumor-suppressing function of the BRCA1 protein.  
In order to investigate whether the drug-damaged BRCA1 is able to transactivate the 
expression of a firefly luciferase gene, DNA repair-proficient MCF-7 cells were transiently 
transfected with the cisplatin-damaged pBIND-BRCT along with the reporter plasmid 
pG5Luc. The firefly luciferase activity was significantly decreased at a cisplatin 
concentration of 12.5 µM (Fig. 4).  
It has been hypothesized that the BRCT domain could transactivate the expression of another 
reporter gene. The reporter gene pSV-β-galactosidase was used for this purpose. It was of 
interest, that the level of transactivation was significantly higher when co-transfected with the 
pBIND-BRCT than with the parental pBIND (Fig. 5). This indicated that the GAL4-BRCT 
domain may stimulate the pSV-β-galactosidase. However, the expression of β-galactosidase 
was decreased to the level of β-galactosidase alone when co-transfected with the platinated 
pBIND-BRCT. It was again of interest that, β-galactosidase expression was dramatically 
diminished when both the pSV-β-galactosidase and the pBIND-BRCT were platinated (Fig. 6). 
Expression of β-galactosidase from the pSV-β-galactosidase can be transactivated both by the 
GAL4 domain of the pBIND and pBIND-BRCT. Acting upon the GAL4 DNA sequence 
similarity, the GAL4 protein alone can stimulate the expression of β-galactosidase. However, 
the degree of transactivation was slightly higher by the pBIND-BRCT. This indicates that the 
BRCT domain on the fusion protein is able to transactivate the β-galactosidase gene-bearing 
pSV-β-galactosidase. When platinated pSV-β-galactosidase is co-transfected with the pBIND 
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or the pBIND-BRCT, a relatively lower expression of β-galactosidase was observed. The 
transcription level of β-galactosidase expression was reduced from 2-2.5 fold to 1.3 fold in both 
plasmids. Considering the data from the proficiency in repairing cisplatin-BRCA1 adducts, it 
demonstrated that over 80% of the DNA lesion was repaired 8 h after cisplatin removal. Thus, 
it is possible that, during the repair time, RNA polymerase II or other transcriptional machineries 
may be blocked at any lesion on DNA (Jung & Lippard, 2003, 2006; Tornaletti et al., 2003).  
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Fig. 4. Time course of firefly luciferase expression. The pBIND-BRCT was incubated with 
cisplatin at concentrations of 0, 12.5, 25 and 50 μM and then co-transfected with the pG5Luc 
plasmid into MCF-7 cells. A cell lysate was prepared at 10, 16, 24 and 36 h after transfection. 
Firefly luciferase expression is detected by the Dual-Luciferase® Reporter Assay System. The 
data were derived from four independent experiments ± standard deviations (SD) 
(Ratanaphan et al., 2009). 
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Fig. 5. Transcriptional transactivation. The pBIND or pBIND-BRCT was co-transfected with 
pSV-ǃ-galactosidase. Cell lysates were prepared at 16 h after transfection. ǃ-galactosidase 
activity was detected using the ǃ-galactosidase assay. The data were derived from four 
independent experiments ± standard deviations (SD) (Ratanaphan et al., 2009). 
Several investigations have revealed transcriptional inhibition on DNA templates, 
containing the site-specific Pt-DNA adducts. The mammalian RNA polymerase II and E. coli 
RNA polymerase did not catalyze the transcriptional reactions when the DNA template 
strands carried the 1,2-intrastrand d(GpG) and d(ApG) adducts, whereas those polymerases 
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Fig. 6. Transcriptional transactivation of platinated pBIND-BRCT on platinated pSV-ǃ-
galactosidase. The platinated pSV-ǃ-galactosidase (with cisplatin at a concentration of 12.5 
μM) was co-transfected with non-platinated pBIND and pBIND-BRCT or platinated pBIND-
BRCT. Cell lysates were prepared at 16 h after transfection. ǃ-galactosidase expression was 
detected using the ǃ-galactosidase assay. The data were derived from four independent 
experiments ± standard deviations (SD) (Ratanaphan et al., 2009). 
could transcribe the complementary templates which had no DNA lesions on the template 
strands (Corda et al., 1991). Transcription of globally platinated DNA templates by SP6 and 
T7 RNA polymerases were also blocked primarily at 1,2-d(GpG) and d(ApG) Pt adducts, 
and to a lesser extent at the interstrand crosslink (Tornaletti, 2005). Bifunctional Pt-DNA 
adducts were much more effective at impeding transcription progression than 
monofunctional DNA adducts (Tornaletti, 2005). Moreover, cisplatin caused a dose-
dependent inhibition of mRNA synthesis. Treatment of human fibroblast cells with 50 µM 
cisplatin for 24 h resulted in a 55% decrease in mRNA level and a reduced expression of 
p21WAF1 protein. This indicated that cisplatin inhibited the transcription of the p21WAF1 gene 
(Ljungman et al., 1999). Recently, the processing of site-specific Pt-DNA crosslinks in 
mammalian cells was investigated (Ang et al., 2010). Site-specific platinated 
oligonucleotides, containing 1,2-d(GpG) and 1,3-d(GpTpG) adducts, were inserted into an 
expression vector between its promoter and a luciferase reporter gene. Transcription 
inhibitions that occurred by blocking passage of the RNA polymerase complex through the 
1,2-d(GpG) and 1,3-d(GpTpG) adducts were 50% and 37.7% of the unplatinated controls for 
vectors, repectively. An X-ray crystal structure of RNA polymerase II showed stalling at the 
1,2-intrastrand d(GpG) crosslink to explain the physical block of transcription by the 
cisplatin-DNA adduct (Damsma et al., 2007). Disruption of chromatin remodeling was 
another mechanism by which a cisplatin adduct could interfere with transcription. 
Nucleosomal DNA, containing the 1,2-d(GpG) or 1,3-d(GpTpG) intrastrand crosslinks, 
enforced a characteristic rotational positioning of the DNA around the histone octamer such 
that the Pt adduct faced inward towards the histone core (Ober and Lippard, 2008). 
Increased solvent accessibility of the platinated DNA strand was observed, and this 
indicated it might be caused by a structural perturbation in proximity of the DNA lesion. In 
addition, the nucleosomes treated with cisplatin exhibited a significant decrease in heat-
induced mobility (Wu et al., 2008). These effects also indicated that a cisplatin assault could 
inhibit transcription by altering the native nucleosomal organization, and limiting the 
nucleosomal sliding that protected access of the RNA polymerase to the DNA template.  
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It has been suggested that inhibition of transcription by cisplatin was a critical determinant 
of cell-cycle arrest in the G2 phase because cells could not synthesize the mRNA necessary 
to pass into mitosis, and this eventually led to apoptosis. Possible mechanisms to explain 
this inhibitory process can be divided into three categories; (1) hijack of transcription factors 
(2) physical block of RNA polymerase, and (3) inhibition of chromatin remodeling (Todd & 
Lippard, 2009). A number of proteins have been identified that specifically recognize the 
distorted Pt-DNA adducts, including transcription factors. The upstream binding factor 
(UBF), a member of the HMG-domain proteins, is a ribosomal RNA transcription factor. 
hUBF can bind the 1,2-intrastrand adducts with a high Kd of 60 pM (Jordan & Carmo-
Fonseca, 1998). Treatment of DNA with cisplatin inhibited ribosomal RNA synthesis by 
competing with hUBF for its natural binding site in an in vitro transcription assay (Zhai et 
al., 1998). The TATA-binding protein (TBP) is a critical transcription factor for all three 
mammalian RNA polymerases (pol I, II, and III). TBP binding to the DNA duplex, 
containing the 1,2-intrastrand d(GpG) crosslinks of cisplatin, was similar to that of the 
TATA-promoter binding in terms of structural and affinity aspects with a Kd of 0.3 nM (Jung 
et al., 2001). It was shown that TBP interacted directly with cisplatin-damaged DNA, and the 
introduction of exogenous cisplatin-modified DNA into the HeLa whole cell extract could 
sequester TBP and inhibit transcription 3-to 4-fold more than undamaged DNA (Vichi et al., 
1997). Collectively, the failure of RNA synthesis resulted from the hijack of transcription 
factors by Pt-DNA adducts, that prevented the assembly of transcriptional elongation 
complexes at their normal promoter sequence and inhibited the transcriptional process. 
Significant reduction in transcriptional transactivation of cisplatin-modified BRCA1 in the 
presence of a second expression vector containing multiple cisplatin-damaged sites could 
address the lack of or the unavailability of cellular transcription factors at cisplatin-BRCA1 
lesions. Damage of BRCA1, if not properly repaired, may lead to its functional impairment 
in cancerous cells which ultimately induce programed cell death. 
7.3 Cisplatin binding to the BRCA1 RING domain 
The types of adduct formed with cisplatin are distinctive and dependent on the accessibility 
of the platinum center and protein side-chains (Ivanov et al., 1998; Peleg-Shulman et al., 
2002). The BRCA1 RING domain has been found to form favourable intramolecular and 
intermolecular cross-links caused by cisplatin (Atipairin et al., 2010). Although cisplatin has 
been demonstrated to induce protein dimerization and has caused perturbations in some 
protein structures, the secondary structure of the BRCA1 RING domain in the apo-form was 
maintained and underwent more folded structural rearrangement after increasing cisplatin 
concentrations as judged by an increase in the negative CD spectra at 208 and 220 nm. It was 
possible that cisplatin might bind to the unoccupied Zn2+-binding sites and caused the 
structural changes. The binding constant of the in vitro platination was 3.00 ± 0.11 x 106 M-1, 
and the free energy of binding (∆G) was -8.68 kcal Mol-1. In addition, the CD spectra of 
BRCA1 pre-incubated with Zn2+ gave identical profiles to indicate that cisplatin could 
interact with other residues rather than the Zn2+-binding sites and barely affected the overall 
conformation of the Zn2+-bound BRCA1. In order to locate the binding site of cisplatin on 
the BRCA1 (1-139) protein, in-gel tryptic digestion of the free BRCA1 and the cisplatin-
BRCA1 adducts (molar ratio 1:1) were subjected to analysis by LC-MS. A unique fragment 
ion of 656.292+ was obtained from the cisplatin-BRCA1 adduct digests. Tandem mass 
spectrometric analyses of this fragment ion indicated that the ion arose from 
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[Pt(NH3)2(OH)]+ that was attached to a BRCA1 peptide 111ENNSPEHLK119 (Fig. 7) (Berners-
Price et al., 1992). 
 
 
Fig. 7. The product-ion spectrum of the MS/MS analysis for the 656.292+ ion. It indicated that 
[Pt(NH3)2(OH)]+ is attached to a peptide 111ENNSPEHLK119 of BRCA1 (Atipairin et al., 2010). 
7.4 Thermal stability of the cisplatin-BRCA1 adducts 
Thermal denaturation was monitored by circular dichroism (CD) to follow heat-induced 
unfolding which determined the effect of cisplatin binding on the stability of the BRCA1 
RING domain. The BRCA1(1-139) protein pre-incubated with or without Zn2+ was 
incubated with cisplatin, and the CD spectra showed identical changes with an increase in 
ellipticity when the temperature was raised from 15°C to 95°C (Fig. 8). It indicated that the 
folded proteins gradually lost their ordered structures. When cooling to 20°C after being 
heated at 95°C, the CD spectrum partially recovered. This indicated that the reversibility of 
the unfolding/refolding process was incomplete. The melting temperatures of the BRCA1(1-
139) proteins were about 74°C and 83°C in the absence and presence of Zn2+, respectively 
(Fig. 9). This indicated that the BRCA1 RING domain was more thermostable by about 9°C 
upon Zn2+-binding. Thus, it supported the important role of Zn2+ in the determination and 
stabilization of the local secondary structure in the RING domain. It was notable that 
cisplatin at a concentration of 10 µM had similar melting temperatures to those observed for 
Zn2+ binding to the BRCA1 RING domain. However, higher melting temperatures were 
observed at a 10-fold concentration of cisplatin (100 µM). These data indicated that cisplatin 
binding to the BRCA1 RING domain conferred an enhanced thermostability by 13°C. 
Resistance to thermal denaturation of the cisplatin-modifed BRCA1 RING domain might 
result from the favourably intramolecular and intermolecular crosslinks driven by the free 
energy (Atipairin et al., 2010). 
7.5 Inactivation of BRCA1 E3 ligase activity by cisplatin 
To gain further insights into the functional consequences of cisplatin-induced BRCA1, the 
BRCA1 RING protein was platinated in vitro by cisplatin at various concentrations. The 
results showed that the relative E3 ligase activity was inversely proportional to the 
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Fig. 8. Thermal transition of the cisplatin-BRCA1 adducts in the presence of Zn2+. The 
BRCA1(1-139) proteins (10 µM) after pre-incubation with a 3 molar equivalent ratio of Zn2+ to 
protein were mixed with cisplatin concentrations of 10 µM. Samples were incubated in the 
dark at ambient temperature for 24 h. The measurements were performed from 15°C to 95°C 
with a heating rate of 1°C/min. After heating to 95°C, the measurement at 20°C was also 
performed. The CD spectra were plotted between the mean residue ellipticity and wavelength 
(Atipairin et al., 2010). 
 
 
Fig. 9. Thermal denaturation curves of the cisplatin-BRCA1 adducts. The BRCA1(1-139) 
protein (10 µM) without Zn2+ and after pre-incubation with a 3 molar equivalent ratio of 
Zn2+ to protein were mixed with various concentrations of cisplatin (0, 10, and 100 µM). 
Samples were incubated in the dark at ambient temperature for 24 h before CD 
measurements. The CD signals at 208 nm were measured, and the unfolded fraction as a 
function of temperature was plotted (Atipairin et al., 2010). 
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concentration of the drug (Fig. 10). An increase in platinum concentration was accompanied 
by a high amount of BRCA1 adducts and a low amount of native BRCA1 protein. To address 
whether the inhibition of the E3 ligase activity resulted from the formation of BRCA1 adducts 
or a reduced amount of the BRCA1 subunit, a ten-fold excess amount of the platinated BRCA1 
was assayed for the E3 ligase activity. The result demonstrated that platination of BRCA1 was 
indeed involved in the inhibition of the E3 ligase activity (Atipairin et al., 2011a).  
 
 
Fig. 10. In vitro ubiquitin ligase activity of cisplatin-BRCA1 complexes. Two µg of the drug-
BRCA1 adducts with a number of defined concentrations of cisplatin was assayed for the 
ubiquitin ligase activitiy. An apparent ubiquitinated product (as indicated by the filled 
diamond) was markedly reduced as the concentration of platinum increased (Atipairin et 
al., 2011a). 
8. Conclusion 
We have demonstrated an in vitro inactivation of BRCA1/BRCA1 by the anticancer 
platinum drug cisplatin. The transcriptional activation of cisplatin-modified BRCA1, when 
tested in a “one-hybrid GAL4 transcriptional assay”, was inversely proportional to 
cisplatin doses and was dramatically diminished in the presence of a second expression 
vector containing multiple cisplatin-damaged sites. This indicates a repair-mediated 
transcriptional transactivation of cisplatin-damaged BRCA1 as well as the lack or 
unavailability of cellular transcription factors at cisplatin-BRCA1 lesions. The BRCA1 
protein contained a preformed structure in the apo-form with structural changes and 
more resistance to limited proteolysis after Zn2+ binding. Cisplatin-bound protein 
exhibited an enhanced thermostability, resulting from the favourable intermolecular 
crosslinks driven by the free energy. Only the apo-form, not the holo-form, of BRCA1 
underwent a more folded structural rearrangement with the retention of protein structure 
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upon cisplatin binding with the preferential His117 site of the BRCA1 peptide 111Glu-Asn-
Asn-Ser-Pro-Glu-His-Leu-Lys119. BRCA1 E3 ubiquitin ligase activity was also inactivated 
by the drug. These data could raise the possibility of selectively targeting the BRCA1 
DNA repair for cisplatin in cancer chemotherapy.  
As mentioned earlier, the BRCA1-BARD1 RING complex has an E3 ubiquitin ligase function 
that plays essential roles in response to DNA damage and DNA repair. Evidence from 
several preclinical and clinical studies have provided data showing that many cancer-
predisposing mutations within the BRCA1 RING domain demonstrated a loss of ubiquitin 
ligase and repair of DNA double-strand break activities (Atipairin, et al., 2011a, 2011b; 
Morris et al., 2006, 2009; Ransburgh et al., 2010). Furthermore, the BRCA1-associated cancers 
conferred a hypersensitivity to ionizing radiations and chemotherapeutic agents. Therefore, 
it would be of great interest to identify a relationship between BRCA1-mediated 
ubiquitination and chemosensitivity by approaching the BRCA1 RING domain as a 
potentially molecular target or predictor with cisplatin. 
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